View Author
patient liver treatment disease study polycystic lanreotide hepatitis volume group polycystic liver disease liver volume month kidney amantadine brosi hepatology placebo signi table netherland effect university result 12 months polycystic kidney disease adpkd remission radboud university nijmegen range mycophenolate mofetil liver fi brosis response department arthritis biopsy kidney volume therapy gastroenterology ficant trial syndrome change anti-ccp 6 months liver biopsy difference hepatitis c nijmegen polycystic liver fibrotest center baseline mycophenolate overlap aliment pharmacol fibroscan antibody analysis symptom mofetil reactivity autosomal serum mutation diagnosis follow-up aza-intolerance peptide hepatol hepatic aza-nonresponse genotype psoriasis somatostatin value treatment failure psoriasis patients ribavirin cohort
8 Most Recent Publications
|
The long-term outcome of patients with polycystic liver disease treated with lanreotide
(Article)
Chrispijn, M. Nevens, F. Drenth, J.P.H. Gevers, T.J.G. Vanslembrouck, R. Oijen, M.G.H. van Coudyzer, W. Hoffmann, A.L. Dekker, H.M. Man, R.A. de Keimpema, L. van |
2012-01-01
|
|
Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes: Authors' reply
(Article)
Baven-Pronk, A.M.C. Coenraad, M.J. Koek, G.H. Nieuwkerk, C.M.J. van Bouma, G. Brouwer, J.T. Hoek, B. van Buuren, H.R. van Man, R.A. de Erpecum, K.J. van Lamers, M.M.H. Drenth, J.P.H. Berg, A.P. van den Beuers, U. Ouden, J. den |
2011-09-01
|
|
The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes
(Article)
Baven-Pronk, A.M.C. Coenraad, M.J. Koek, G.H. Nieuwkerk, C.M.J. van Bouma, G. Brouwer, J.T. Hoek, B. van Buuren, H.R. van Man, R.A. de Erpecum, K.J. van Lamers, M.M.H. Drenth, J.P.H. Berg, A.P. van den Beuers, U. Ouden, J. den |
2011-07-01
|
|
Patients with isolated polycystic liver disease referred to liver centres: Clinical characterization of 137 cases
(Article)
Keimpema, L. van Koning, D.B. de Hoek, B. van Berg, A.P. van den Oijen, M.G.H. van Man, R.A. de Nevens, F. Drenth, J.P.H. |
2011-01-01
|
|
No beneficial effects of amantadine in treatment of chronic hepatitis C patients
(Article)
Soest, H. van Schaar, P.J. van der Sluys Veer, A. van der Siersema, P.D. Schipper, M.E.I. Erpecum, K.J. van Boland , G.J. Koek, G.H. Vries, R.A. de Ooteghem, N.A. Hoek, B. van Drenth, J.P.H. Vrolijk, J.M. Lieverse, R.J. Houben, P. |
2010-07-01
|
|
Lanreotide Reduces the Volume of Polycystic Liver: A Randomized, Double-Blind, Placebo-Controlled Trial
(Article)
Keimpema, L. van Nevens, F. Vanslembrouck, R. Oijen, M.G.H. van Hoffmann, A.L. Dekker, H.M. Man, R.A. de Drenth, J.P.H. |
2009-11-01
|
|
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis
(Article)
Berends, M.A.M. Snoek, J. Jong, E.M. de Krieken, J.H.J.M. van Knegt, R.J. de Oijen, M.G.H. van Kerkhof, P.C.M. van de Drenth, J.P.H. |
2007-06-01
|
|
Anti-cyclic citrullinated peptide positivity in non-rheumatoid arthritis disease samples: Citrulline-dependent or not?
(Article)
Vannini, A. Cheung, K. Zendman, A.J.W. Fusconi, M. Stammen-Vogelzangs, J. Drenth, J.P.H. Dall'Aglio, A.C. Bianchi, F.B. Bakker-Jonges, L.E. Venrooij, W.J. van Pruijn, G.J.M. |
2007-04-01
|
